Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Ji-Lin Guan"'
Autor:
She-Juan An, Zhi-Hong Chen, Jian Su, Xu-Chao Zhang, Wen-Zhao Zhong, Jin-Ji Yang, Qing Zhou, Xue-Ning Yang, Ling Huang, Ji-Lin Guan, Qiang Nie, Hong-Hong Yan, Tony S Mok, Yi-Long Wu
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e40109 (2012)
BACKGROUND: Appropriate patient selection is needed for targeted therapies that are efficacious only in patients with specific genetic alterations. We aimed to define subgroups of patients with candidate driver genes in patients with non-small cell l
Externí odkaz:
https://doaj.org/article/b3085ec0151349ea8c82382255208903
Autor:
Qing Wang, Meng-Li Huang, Jian-Hua Liu, Ji-Lin Guan, Yu-Wei Cong, Ling Huang, Ke-Fei Huang, Yao-Xu Chen
Publikováno v:
World Journal of Gastrointestinal Oncology
BACKGROUND Human epidermal growth factor receptor 2 (HER2) amplification is a molecular driver for a subset of colorectal cancers (CRCs) and one of the major causes of anti-epidermal growth factor receptor (EGFR) treatment failure. Compared to dual a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6522aaa2be616b2b4541af398a91d7a0
https://doi.org/10.4251/wjgo.v12.i9.1065
https://doi.org/10.4251/wjgo.v12.i9.1065
Autor:
Yi-Long Wu, Xu-Chao Zhang, Zhu Zeng, Long-Hua Guo, Lu-Lu Yang, Chong-Rui Xu, Jin-Ji Yang, Yan-yan He, Ji-lin Guan, Hong-Hong Yan, Wen-Zhao Zhong, Fei-Yu Niu
Publikováno v:
Clinical Lung Cancer. 15:441-447
TNM stage remains the most important prognostic factor in clinical practice. The 7th edition lung cancer staging system has not considered some important prognostic factors, such as the number of metastatic organ sites and the molecular biologic char
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6798edcec5ddc2646d9989ac67fdf469
https://doi.org/10.1016/j.cllc.2014.06.006
https://doi.org/10.1016/j.cllc.2014.06.006
Autor:
Yi-Long Wu, She-Juan An, Lu-Lu Yang, Xu-Chao Zhang, Zhen Wang, Yan-yan He, Jin-Ji Yang, Hua-Jun Chen, Xue-Ning Yang, Chong-Rui Xu, Wen-Zhao Zhong, Ji-lin Guan, Hong-Hong Yan
Publikováno v:
The Oncologist. 19:1084-1090
Background. Substantial progress has been made in the treatment of malignancies in the People's Republic of China in recent years. The goal of this study was to identify the extent to which national treatment guidelines are being used to customize pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77a9fad0782f56f3e44df210819e38e5
https://doi.org/10.1634/theoncologist.2014-0007
https://doi.org/10.1634/theoncologist.2014-0007
Autor:
Zhi-yong Chen, Jian Su, Yi-Long Wu, Hong-Hong Yan, She-Juan An, Zhimin Huang, Jin-Ji Yang, Wen-Zhao Zhong, Ji-lin Guan, Zhi-Hong Chen, Qiang Nie, Xu-Chao Zhang
Publikováno v:
Annals of Surgical Oncology. 20:1381-1388
The prognostic and predictive value of KRAS mutations in patients with lung cancer is controversial. Biases in disease stage, treatment regimen, small-scale patient studies, and biomarker status have led to inconsistent results in previous reports. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d06852f558051d4ad4f47263a4f60bef
https://doi.org/10.1245/s10434-012-2754-z
https://doi.org/10.1245/s10434-012-2754-z
Autor:
Qiang Nie, Jin Ji Yang, Ling Huang, X.-N. Yang, She-Juan An, Jian Su, Hong hong Yan, Yi-Long Wu, Zhi-Hong Chen, X. Zhang, Wen-Zhao Zhong, Tony Mok, Ji Lin Guan, Qing Zhou
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e40109 (2012)
PLoS ONE
PLoS ONE
BACKGROUND: Appropriate patient selection is needed for targeted therapies that are efficacious only in patients with specific genetic alterations. We aimed to define subgroups of patients with candidate driver genes in patients with non-small cell l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a12ee97c1edc378329885d8e71764df7
http://europepmc.org/articles/PMC3387024?pdf=render
http://europepmc.org/articles/PMC3387024?pdf=render
Autor:
Hong-Hong Yan, Yi-Sheng Huang, Ji-lin Guan, Jian Su, Zhimin Huang, She-Juan An, Wen-Zhao Zhong, Zhi-Hong Chen, Y-L. Wu, X. Zhang
Publikováno v:
Journal of Clinical Oncology. 30:e18090-e18090
e18090 Background: At present, prognostic and predictive value for KRAS mutation in lung cancer patients remains to be controversial. Biases in disease stage, treatment regimens and small scale patient population led to inconsistent results in previo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::218518a053743c3dc130c3dc8b51dbdf
https://doi.org/10.1200/jco.2012.30.15_suppl.e18090
https://doi.org/10.1200/jco.2012.30.15_suppl.e18090
Autor:
Wen-Zhao Zhong, Xu-Chao Zhang, Hong-Hong Yan, Zhi-Hong Chen, Qiang Nie, Jin-Ji Yang, Ji-lin Guan, She-Juan An, Qing Zhou, Yi-Long Wu, Tony Mok, Jian Su, Xue-Ning Yang, Ling Huang
Publikováno v:
Cancer Research. 72:4573-4573
Purpose Patient selection is needed as target therapy had efficacy only to the subsets of patients with specific genetic alterations. We aimed to clarify the subgroups for enriching the patients with candidate driver genes. Patients and Methods The p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5f37d30028286354cbd32161888c30d
https://doi.org/10.1158/1538-7445.am2012-4573
https://doi.org/10.1158/1538-7445.am2012-4573
Autor:
Yan-yan He, Xu-chao Zhang, Jin-ji Yang, Fei-yu Niu, Zhu Zeng, Hong-hong Yan, Chong-rui Xu, Ji-lin Guan, Wen-zhao Zhong, Lu-lu Yang, Long-hua Guo, Yi-long Wu
Publikováno v:
Clinical Lung Cancer; Nov2014, Vol. 15 Issue 6, p441-447, 7p